Compare Microsoft (MSFT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Revvity Inc — how do they compare? Microsoft trades at $528.15 (market cap $3.88T), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Microsoft is far larger — about 228.5× Revvity Inc's market cap, and Microsoft pays the higher dividend (0.75%). Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Revvity Inc for 12 Days on average.
| MSFT | RVTY | |
|---|---|---|
Market Cap | $3.88T | $16.98B |
Volume | 19,593,392 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $542.07 | $157.36 |
52-Week Low | $352.83 | $82.26 |
Typical Hold Time | 142 Days | 12 Days |
Enterprise Value | $3.86T | $19.30B |
Dividend Yield | 0.75% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft trades at $529.76, up 0.09% with strong bullish technical signals and consistent earnings beats. The company maintains robust fundamentals with $281.72B revenue, 40.31% net margin, and positive cash flow. Recent analyst coverage shows 82% buy ratings with a $571.76 consensus target, while technical indicators suggest support at $526 and resistance at $533.
Outlook remains positive with AI leadership driving growth, though elevated P/E of 29.11 and competitive pressures present risks. The stock offers solid dividend income and institutional support, but investors should monitor capital expenditure trends and market rotation away from mega-cap tech stocks.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
